| 1 |
35115097 | Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention. | 2022 Feb 8 |
1 |
| 2 |
35237927 | Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives. | 2022 Apr |
1 |
| 3 |
35570383 | A Review of the Role of the Antiplatelet Drug Ticagrelor in the Management of Acute Coronary Syndrome, Acute Thrombotic Disease, and Other Diseases. | 2022 May 16 |
1 |
| 4 |
35619249 | Comparison of aspirin and P2Y12 inhibitors for secondary prevention of ischaemic stroke: A systematic review and meta-analysis. | 2022 May 26 |
2 |
| 5 |
33461308 | Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. | 2021 Mar 23 |
1 |
| 6 |
33488022 | P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin? | 2021 Jan |
2 |
| 7 |
33555916 | Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. | 2021 Feb 9 |
1 |
| 8 |
33706989 | The Future of Aspirin Therapy in Cardiovascular Disease. | 2021 Apr 1 |
1 |
| 9 |
33758122 | Improving Outcomes in Cardiovascular Diseases: A Review on Vorapaxar. | 2021 Mar 19 |
1 |
| 10 |
33847681 | Dual therapy with an oral non-vitamin K antagonist and a P2Y12 inhibitor vs triple therapy with aspirin, a P2Y12 inhibitor and a vitamin K antagonist for the treatment of diabetes mellitus patients with co-existing atrial fibrillation following percutaneous coronary intervention: A meta-analysis. | 2021 Apr 16 |
1 |
| 11 |
33979377 | Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy. | 2021 |
1 |
| 12 |
34003664 | Early P2Y12 Receptor Monotherapy Following Drug-Eluting Stenting: Is It Time to Give Up Aspirin? | 2021 May |
1 |
| 13 |
34011436 | P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials. | 2021 Jul 1 |
1 |
| 14 |
34042199 | The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials). | 2021 Jul |
1 |
| 15 |
34202960 | Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial. | 2021 Jun 20 |
1 |
| 16 |
34589424 | P2RY12-Inhibitors Reduce Cancer-Associated Thrombosis and Tumor Growth in Pancreatic Cancers. | 2021 |
1 |
| 17 |
34604694 | Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist. | 2021 Jul |
1 |
| 18 |
34776464 | P2Y12 Inhibitors Exacerbate Low-dose Aspirin-induced Small Bowel Injury in Dual Antiplatelet Therapy. | 2021 |
1 |
| 19 |
34824680 | Aspirin in the Modern Era of Cardiovascular Disease Prevention. | 2021 |
1 |
| 20 |
34915778 | Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events. | 2021 Dec |
1 |
| 21 |
31542850 | Comorbidity and low use of new antiplatelets in acute coronary syndrome. | 2020 Aug |
1 |
| 22 |
31665395 | A 70-Year-Old Female with Unexpected Platelet Function Testing Results. | 2020 May 6 |
1 |
| 23 |
32551860 | The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. | 2020 Aug 11 |
4 |
| 24 |
32779497 | Pooled Analysis of Bleeding, Major Adverse Cardiovascular Events, and All-Cause Mortality in Clinical Trials of Time-Constrained Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention. | 2020 Aug 18 |
1 |
| 25 |
32853794 | Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis. | 2020 Dec |
1 |
| 26 |
32921373 | The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience. | 2020 Oct |
1 |
| 27 |
33302757 | When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y12 Inhibition Induced by Ticagrelor. | 2020 Dec 15 |
1 |
| 28 |
33316184 | Stopping aspirin 1 to 3 mo after PCI reduces bleeding without increasing MACE vs. continued DAPT. | 2020 Dec 15 |
1 |
| 29 |
29461906 | How does measurement of platelet P-selectin compare with other methods of measuring platelet function as a means of determining the effectiveness of antiplatelet therapy? | 2019 |
1 |
| 30 |
29890239 | A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. | 2019 Jan |
3 |
| 31 |
30883047 | Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. | 2019 May 9 |
1 |
| 32 |
30895761 | Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study. | 2019 Apr |
1 |
| 33 |
31267433 | Different Clopidogrel Response Elicited by Lansoprazole or Esomeprazole in Patients Undergoing Neurointervention with Dual Antiplatelet Therapy. | 2019 Oct |
1 |
| 34 |
31557056 | Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. | 2019 Dec 3 |
1 |
| 35 |
31745500 | Ticagrelor and Statin Interaction Induces Rhabdomyolysis and Acute Renal Failure: Case reports and Scoping Review. | 2019 |
1 |
| 36 |
29129512 | Thieno[2,3-b]pyridine derivatives are potent anti-platelet drugs, inhibiting platelet activation, aggregation and showing synergy with aspirin. | 2018 Jan 1 |
1 |
| 37 |
29345592 | Prolonging Ticagrelor Beyond a Year of Acute Coronary Syndrome: Worth or Harmful? | 2018 |
1 |
| 38 |
29443445 | Aspirin withdrawal in patients treated with ticagrelor presenting with non-ST elevation myocardial infarction. | 2018 Apr |
2 |
| 39 |
29447787 | Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial. | 2018 Mar |
1 |
| 40 |
29679301 | Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry. | 2018 Apr |
1 |
| 41 |
30498334 | Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: a network meta-analysis. | 2018 |
1 |
| 42 |
30575713 | Perioperative management of patients who are receiving antiplatelet therapy: a case-based, evidence-informed approach. | 2018 Dec 21 |
1 |
| 43 |
28184261 | Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications. | 2017 Feb |
1 |
| 44 |
28362883 | Use of Aspirin and P2Y12 Response Assays in Detecting Reversal of Platelet Inhibition With Platelet Transfusion in Patients With Traumatic Brain Injury on Antiplatelet Therapy. | 2017 Jan 1 |
2 |
| 45 |
28385176 | Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome. | 2017 Jun 1 |
1 |
| 46 |
28618904 | Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. | 2017 Jun |
1 |
| 47 |
28844193 | Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. | 2017 Oct 19 |
1 |
| 48 |
28844979 | Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation. | 2017 Nov |
1 |
| 49 |
28975318 | In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events. | 2017 Sep 19 |
1 |
| 50 |
26516174 | Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of platelet to synthesize thromboxane A2. | 2016 Nov 21 |
2 |